Thus, the observed differences in sensitivity of CRC to vitamin D analogues may dependent on the unique properties of the cancer cells (37,38), including the degree of expression of VDR and CYP24A1 (49), as well as on the molecular structure of the vitamin D3 analogue. The gene discussed is VDR; the disease is cancer.